Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types

• Published in: Molecular cancer Vol. 20; no. 1; p. 67
• Main Authors: Shen, Sipeng, Zhang, Ruyang, Jiang, Yue, Li, Yi, Lin, Lijuan, Liu, Zhonghua, Zhao, Yang, Shen, Hongbing, Hu, Zhibin, Wei, Yongyue, Chen, Feng
• Format: Journal Article
• Language: English
• Published: England BioMed Central 13.04.2021; BMC
• Subjects: Breast cancer; Cancer; Cell cycle; Datasets; Gene expression; Genomes; Kinases; Letter to the Editor; Localization; Metastases; Metastasis; MicroRNAs; Multi-omics; Mutation; N6-Methyladenosine; Non-coding RNA; Pan-cancer; Population; Principal components analysis; RNA modification; RNA-protein interactions; Signal transduction; Survival analysis; Survival outcome; Tumor microenvironment; Tumors; Wnt protein; N6-Methyladenosine; Pan-cancer; Survival outcome; Multi-omics
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-021-01362-2

N6-Methyladenosine (m6A) is an RNA modification that interacts with numerous coding and non-coding RNAs and plays important roles in the development of cancers. Nonetheless, the clinical impacts of m6A interactive genes on these cancers largely remain unclear since most studies focus only on a single cancer type. We comprehensively evaluated m6A modification patterns, including 23 m6A regulators and 83 interactive coding and non-coding RNAs among 9,804 pan-cancer samples. We used clustering analysis to identify m6A subtypes and constructed the m6A signature based on an unsupervised approach. We used the signatures to identify potential m6A modification targets across the genome. The prognostic value of one target was further validated in 3,444 samples from six external datasets. We developed three distinct m6A modification subtypes with different tumor microenvironment cell infiltration degrees: immunological, intermediate, and tumor proliferative. They were significantly associated with overall survival in 24 of 27 cancer types. Our constructed individual-level m6A signature was associated with survival, tumor mutation burden, and classical pathways. With the signature, we identified 114 novel genes as potential m6A targets. The gene shared most commonly between cancer types, BCL9L, is an oncogene and interacts with m6A patterns in the Wnt signaling pathway. In conclusion, m6A regulators and their interactive genes impact the outcome of various cancers. Evaluating the m6A subtype and the signature of individual tumors may inform the design of adjuvant treatments.